deltatrials
Completed PHASE2 INTERVENTIONAL 2-arm NCT04030026

A Study of Nalbuphine (Extended Release) ER in Idiopathic Pulmonary Fibrosis (IPF) for Treatment of Cough (CANAL)

A Phase 2, Double-blind, Randomized, Placebo-controlled, Two-Treatment, Two-Period Crossover Efficacy and Safety Study in Idiopathic Pulmonary Fibrosis (IPF) With Nalbuphine ER Tablets for the Treatment of Cough

Sponsor: Parexel

Conditions Idiopathic Pulmonary Fibrosis
Interventions NAL ER Placebo
Updated 21 times since 2019 Last updated: May 12, 2025 Started: Oct 29, 2019 Primary completion: May 27, 2022 Completion: May 27, 2022
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Idiopathic Pulmonary Fibrosis and is currently completed. Parexel leads this study, which shows 21 recorded versions since 2019 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~Aug 2019 – ~Sep 2019 · 31 days · monthly snapshot~Sep 2019 – ~Mar 2020 · 6 months · monthly snapshot~Mar 2020 – ~May 2020 · 2 months · monthly snapshot~May 2020 – ~Jul 2020 · 2 months · monthly snapshot~Jul 2020 – ~Oct 2020 · 3 months · monthly snapshot~Oct 2020 – ~Nov 2020 · 31 days · monthly snapshot~Nov 2020 – ~Jan 2021 · 2 months · monthly snapshot~Jan 2021 – ~Feb 2021 · 31 days · monthly snapshot~Feb 2021 – ~Jun 2021 · 4 months · monthly snapshot~Jun 2021 – ~Sep 2021 · 3 months · monthly snapshot~Sep 2021 – ~Dec 2021 · 3 months · monthly snapshot~Dec 2021 – ~Jan 2022 · 31 days · monthly snapshot~Jan 2022 – ~Apr 2022 · 3 months · monthly snapshot~Apr 2022 – ~Sep 2022 · 5 months · monthly snapshot~Sep 2022 – ~Nov 2022 · 2 months · monthly snapshot~Nov 2022 – ~Jun 2023 · 7 months · monthly snapshot~Jun 2023 – ~Jul 2024 · 13 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Jun 2025 · 9 months · monthly snapshot~Jun 2025 – ~Sep 2025 · 3 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

21 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE2

  2. Jun 2025 — Sep 2025 [monthly]

    Completed PHASE2

  3. Sep 2024 — Jun 2025 [monthly]

    Completed PHASE2

  4. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  5. Jun 2023 — Jul 2024 [monthly]

    Completed PHASE2

▶ Show 16 earlier versions

  1. Nov 2022 — Jun 2023 [monthly]

    Completed PHASE2

  2. Sep 2022 — Nov 2022 [monthly]

    Completed PHASE2

    Status: Active Not Recruiting → Completed

  3. Apr 2022 — Sep 2022 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  4. Jan 2022 — Apr 2022 [monthly]

    Recruiting PHASE2

  5. Dec 2021 — Jan 2022 [monthly]

    Recruiting PHASE2

  6. Sep 2021 — Dec 2021 [monthly]

    Recruiting PHASE2

  7. Jun 2021 — Sep 2021 [monthly]

    Recruiting PHASE2

  8. Feb 2021 — Jun 2021 [monthly]

    Recruiting PHASE2

  9. Jan 2021 — Feb 2021 [monthly]

    Recruiting PHASE2

  10. Nov 2020 — Jan 2021 [monthly]

    Recruiting PHASE2

    Status: Active Not Recruiting → Recruiting

  11. Oct 2020 — Nov 2020 [monthly]

    Active Not Recruiting PHASE2

  12. Jul 2020 — Oct 2020 [monthly]

    Active Not Recruiting PHASE2

  13. May 2020 — Jul 2020 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  14. Mar 2020 — May 2020 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  15. Sep 2019 — Mar 2020 [monthly]

    Not Yet Recruiting PHASE2

  16. Aug 2019 — Sep 2019 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Parexel
  • Trevi Therapeutics
Data source: Trevi Therapeutics

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations